1. Home
  2. SPB vs MESO Comparison

SPB vs MESO Comparison

Compare SPB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spectrum Brands Holdings Inc.

SPB

Spectrum Brands Holdings Inc.

HOLD

Current Price

$86.98

Market Cap

2.0B

Sector

Miscellaneous

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.00

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPB
MESO
Founded
1906
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
1994
2005

Fundamental Metrics

Financial Performance
Metric
SPB
MESO
Price
$86.98
$17.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$82.40
N/A
AVG Volume (30 Days)
369.4K
175.2K
Earning Date
05-07-2026
02-26-2026
Dividend Yield
2.31%
N/A
EPS Growth
N/A
N/A
EPS
1.01
N/A
Revenue
$3,802,100,000.00
N/A
Revenue This Year
$2.03
$629.74
Revenue Next Year
$1.85
$30.65
P/E Ratio
$85.31
N/A
Revenue Growth
20.86
N/A
52 Week Low
$49.99
$12.66
52 Week High
$99.06
$21.50

Technical Indicators

Market Signals
Indicator
SPB
MESO
Relative Strength Index (RSI) 46.53 57.18
Support Level $85.81 $16.67
Resistance Level $90.60 $17.10
Average True Range (ATR) 3.07 0.36
MACD -0.48 0.13
Stochastic Oscillator 11.16 69.39

Price Performance

Historical Comparison
SPB
MESO

About SPB Spectrum Brands Holdings Inc.

Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: